JAMA Netw Open:前列腺癌治疗药物促性腺激素释放激素激动剂与患糖尿病男性的心血管疾病风险和高血压有关么?

2022-08-14 AlexYang MedSci原创

评估了2型糖尿病男性患者中,GnRH激动剂、PCa和CVD风险之间的关系。

前列腺癌(PCa)是男性中最常见的癌症之一,2019年全球有超过100万名男性诊断为前列腺癌。PCa男性比没有PCa男性患心血管疾病(CVD)的风险更高。心血管疾病还是PCa男性最常见的死亡原因,占比32%,而PCa仅占20%。

已有研究指出,患2型糖尿病男性的心血管疾病(CVD)风险增加。同时,用于治疗前列腺癌(PCa)的促性腺激素释放激素(GnRH)激动剂与心血管疾病风险的增加有关。近期,来自英国的研究人员在《JAMA Netw Open》上发表文章,评估了2型糖尿病男性患者中,GnRH激动剂、PCa和CVD风险之间的关系

研究为基于人群的队列设计,包括2006年至2016年的纵向数据。研究人员使用这些数据建立了2个大队列,分别为包括患有和未患有PCa的男性队列以及接受和未接受GnRH激动剂的PCa男性队列。数据分析时间为2006年1月至2016年12月。采用了Cox比例风险回归模型分析关联情况。

PCa队列包括5714名男性(中位数[IQR]年龄,72.0[11.0]),非PCa队列包括28445名无PCa男性(中位数[IQR]年龄,72.0[11.0])。GnRH激动剂队列包括692名PCa男性,未接受GnRH激动剂队列包括3460名PCa男性。与不患有PCa的男性相比(危险比[HR],1.25;95%CI,1.16-1.36),以及与与没有接受GnRH激动剂治疗的PCa男性相比(HR,1.53;95%CI,1.35-1.74),接受GnRH激动剂治疗PCa男性的5年CVD风险评分均增加。与未患PCa的男性相比(HR,0.70;95%CI,0.61-0.80),以及与未接受GnRH激动剂治疗的PCa男性相比(HR,0.68;95%CI,0.56-0.82),接受GnRH激动剂治疗的PCa男性血压均下降。

心血管疾病的累积发生率情况

综上所述,在这项基于人群的队列研究中,接受GnRH激动剂治疗PCa的2型糖尿病男性的CVD风险增加。因此,在接受GnRH激动剂治疗的2型糖尿病男性患者中,需要严密控制CVD风险因素。

 

原始出处:

E Lin , Hans Garmo , Mieke Van Hemelrijck et al. Association of Gonadotropin-Releasing Hormone Agonists for Prostate Cancer With Cardiovascular Disease Risk and Hypertension in Men With Diabetes. JAMA Netw Open. Aug 2022

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1921885, encodeId=62a719218850a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri Feb 24 02:31:25 CST 2023, time=2023-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060724, encodeId=e7682060e24bc, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun Jan 22 00:31:25 CST 2023, time=2023-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729724, encodeId=78b61e2972404, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 31 01:31:25 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250247, encodeId=1485125024eea, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>治疗药物<a href='/topic/show?id=bdb9104e4325' target=_blank style='color:#2F92EE;'>#促性腺激素释放激素激动剂#</a>与患<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>男性的<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>疾病风险和<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血压#</a>有关么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌), TopicDto(id=104743, encryptionId=bdb9104e4325, topicName=促性腺激素释放激素激动剂), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管), TopicDto(id=102651, encryptionId=1c1710265113, topicName=高血压)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 13:28:42 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734537, encodeId=1e221e3453743, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Nov 13 06:31:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473347, encodeId=cb8f14e33471c, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499103, encodeId=ad8c149910355, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627884, encodeId=f2b3162e884f9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243650, encodeId=ba59124365058, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Aug 13 19:31:25 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1921885, encodeId=62a719218850a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri Feb 24 02:31:25 CST 2023, time=2023-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060724, encodeId=e7682060e24bc, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun Jan 22 00:31:25 CST 2023, time=2023-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729724, encodeId=78b61e2972404, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 31 01:31:25 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250247, encodeId=1485125024eea, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>治疗药物<a href='/topic/show?id=bdb9104e4325' target=_blank style='color:#2F92EE;'>#促性腺激素释放激素激动剂#</a>与患<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>男性的<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>疾病风险和<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血压#</a>有关么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌), TopicDto(id=104743, encryptionId=bdb9104e4325, topicName=促性腺激素释放激素激动剂), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管), TopicDto(id=102651, encryptionId=1c1710265113, topicName=高血压)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 13:28:42 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734537, encodeId=1e221e3453743, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Nov 13 06:31:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473347, encodeId=cb8f14e33471c, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499103, encodeId=ad8c149910355, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627884, encodeId=f2b3162e884f9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243650, encodeId=ba59124365058, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Aug 13 19:31:25 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1921885, encodeId=62a719218850a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri Feb 24 02:31:25 CST 2023, time=2023-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060724, encodeId=e7682060e24bc, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun Jan 22 00:31:25 CST 2023, time=2023-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729724, encodeId=78b61e2972404, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 31 01:31:25 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250247, encodeId=1485125024eea, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>治疗药物<a href='/topic/show?id=bdb9104e4325' target=_blank style='color:#2F92EE;'>#促性腺激素释放激素激动剂#</a>与患<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>男性的<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>疾病风险和<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血压#</a>有关么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌), TopicDto(id=104743, encryptionId=bdb9104e4325, topicName=促性腺激素释放激素激动剂), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管), TopicDto(id=102651, encryptionId=1c1710265113, topicName=高血压)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 13:28:42 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734537, encodeId=1e221e3453743, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Nov 13 06:31:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473347, encodeId=cb8f14e33471c, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499103, encodeId=ad8c149910355, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627884, encodeId=f2b3162e884f9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243650, encodeId=ba59124365058, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Aug 13 19:31:25 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
    2023-05-31 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1921885, encodeId=62a719218850a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri Feb 24 02:31:25 CST 2023, time=2023-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060724, encodeId=e7682060e24bc, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun Jan 22 00:31:25 CST 2023, time=2023-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729724, encodeId=78b61e2972404, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 31 01:31:25 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250247, encodeId=1485125024eea, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>治疗药物<a href='/topic/show?id=bdb9104e4325' target=_blank style='color:#2F92EE;'>#促性腺激素释放激素激动剂#</a>与患<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>男性的<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>疾病风险和<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血压#</a>有关么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌), TopicDto(id=104743, encryptionId=bdb9104e4325, topicName=促性腺激素释放激素激动剂), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管), TopicDto(id=102651, encryptionId=1c1710265113, topicName=高血压)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 13:28:42 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734537, encodeId=1e221e3453743, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Nov 13 06:31:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473347, encodeId=cb8f14e33471c, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499103, encodeId=ad8c149910355, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627884, encodeId=f2b3162e884f9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243650, encodeId=ba59124365058, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Aug 13 19:31:25 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1921885, encodeId=62a719218850a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri Feb 24 02:31:25 CST 2023, time=2023-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060724, encodeId=e7682060e24bc, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun Jan 22 00:31:25 CST 2023, time=2023-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729724, encodeId=78b61e2972404, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 31 01:31:25 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250247, encodeId=1485125024eea, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>治疗药物<a href='/topic/show?id=bdb9104e4325' target=_blank style='color:#2F92EE;'>#促性腺激素释放激素激动剂#</a>与患<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>男性的<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>疾病风险和<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血压#</a>有关么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌), TopicDto(id=104743, encryptionId=bdb9104e4325, topicName=促性腺激素释放激素激动剂), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管), TopicDto(id=102651, encryptionId=1c1710265113, topicName=高血压)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 13:28:42 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734537, encodeId=1e221e3453743, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Nov 13 06:31:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473347, encodeId=cb8f14e33471c, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499103, encodeId=ad8c149910355, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627884, encodeId=f2b3162e884f9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243650, encodeId=ba59124365058, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Aug 13 19:31:25 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
    2022-11-13 canlab
  6. [GetPortalCommentsPageByObjectIdResponse(id=1921885, encodeId=62a719218850a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri Feb 24 02:31:25 CST 2023, time=2023-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060724, encodeId=e7682060e24bc, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun Jan 22 00:31:25 CST 2023, time=2023-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729724, encodeId=78b61e2972404, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 31 01:31:25 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250247, encodeId=1485125024eea, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>治疗药物<a href='/topic/show?id=bdb9104e4325' target=_blank style='color:#2F92EE;'>#促性腺激素释放激素激动剂#</a>与患<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>男性的<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>疾病风险和<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血压#</a>有关么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌), TopicDto(id=104743, encryptionId=bdb9104e4325, topicName=促性腺激素释放激素激动剂), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管), TopicDto(id=102651, encryptionId=1c1710265113, topicName=高血压)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 13:28:42 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734537, encodeId=1e221e3453743, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Nov 13 06:31:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473347, encodeId=cb8f14e33471c, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499103, encodeId=ad8c149910355, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627884, encodeId=f2b3162e884f9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243650, encodeId=ba59124365058, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Aug 13 19:31:25 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1921885, encodeId=62a719218850a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri Feb 24 02:31:25 CST 2023, time=2023-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060724, encodeId=e7682060e24bc, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun Jan 22 00:31:25 CST 2023, time=2023-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729724, encodeId=78b61e2972404, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 31 01:31:25 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250247, encodeId=1485125024eea, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>治疗药物<a href='/topic/show?id=bdb9104e4325' target=_blank style='color:#2F92EE;'>#促性腺激素释放激素激动剂#</a>与患<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>男性的<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>疾病风险和<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血压#</a>有关么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌), TopicDto(id=104743, encryptionId=bdb9104e4325, topicName=促性腺激素释放激素激动剂), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管), TopicDto(id=102651, encryptionId=1c1710265113, topicName=高血压)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 13:28:42 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734537, encodeId=1e221e3453743, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Nov 13 06:31:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473347, encodeId=cb8f14e33471c, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499103, encodeId=ad8c149910355, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627884, encodeId=f2b3162e884f9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243650, encodeId=ba59124365058, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Aug 13 19:31:25 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1921885, encodeId=62a719218850a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri Feb 24 02:31:25 CST 2023, time=2023-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060724, encodeId=e7682060e24bc, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun Jan 22 00:31:25 CST 2023, time=2023-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729724, encodeId=78b61e2972404, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 31 01:31:25 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250247, encodeId=1485125024eea, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>治疗药物<a href='/topic/show?id=bdb9104e4325' target=_blank style='color:#2F92EE;'>#促性腺激素释放激素激动剂#</a>与患<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>男性的<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>疾病风险和<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血压#</a>有关么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌), TopicDto(id=104743, encryptionId=bdb9104e4325, topicName=促性腺激素释放激素激动剂), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管), TopicDto(id=102651, encryptionId=1c1710265113, topicName=高血压)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 13:28:42 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734537, encodeId=1e221e3453743, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Nov 13 06:31:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473347, encodeId=cb8f14e33471c, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499103, encodeId=ad8c149910355, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627884, encodeId=f2b3162e884f9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243650, encodeId=ba59124365058, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Aug 13 19:31:25 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1921885, encodeId=62a719218850a, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Fri Feb 24 02:31:25 CST 2023, time=2023-02-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060724, encodeId=e7682060e24bc, content=<a href='/topic/show?id=48522e070f0' target=_blank style='color:#2F92EE;'>#促性腺激素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27070, encryptionId=48522e070f0, topicName=促性腺激素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=76d3356, createdName=tongyongming, createdTime=Sun Jan 22 00:31:25 CST 2023, time=2023-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1729724, encodeId=78b61e2972404, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Wed May 31 01:31:25 CST 2023, time=2023-05-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1250247, encodeId=1485125024eea, content=<a href='/topic/show?id=c8ee32526f3' target=_blank style='color:#2F92EE;'>#前列腺癌#</a>治疗药物<a href='/topic/show?id=bdb9104e4325' target=_blank style='color:#2F92EE;'>#促性腺激素释放激素激动剂#</a>与患<a href='/topic/show?id=4f77e665253' target=_blank style='color:#2F92EE;'>#糖尿病#</a>男性的<a href='/topic/show?id=974e51e2810' target=_blank style='color:#2F92EE;'>#心血管#</a>疾病风险和<a href='/topic/show?id=1c1710265113' target=_blank style='color:#2F92EE;'>#高血压#</a>有关么, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32526, encryptionId=c8ee32526f3, topicName=前列腺癌), TopicDto(id=104743, encryptionId=bdb9104e4325, topicName=促性腺激素释放激素激动剂), TopicDto(id=76652, encryptionId=4f77e665253, topicName=糖尿病), TopicDto(id=51728, encryptionId=974e51e2810, topicName=心血管), TopicDto(id=102651, encryptionId=1c1710265113, topicName=高血压)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/Random/55971dc507c93968175ce7cc1e177b372a83869f.jpg, createdBy=f63e4754896, createdName=小小医者, createdTime=Sat Sep 17 13:28:42 CST 2022, time=2022-09-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1734537, encodeId=1e221e3453743, content=<a href='/topic/show?id=d4f412668a4' target=_blank style='color:#2F92EE;'>#NET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12668, encryptionId=d4f412668a4, topicName=NET)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7ea033781210, createdName=canlab, createdTime=Sun Nov 13 06:31:25 CST 2022, time=2022-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1473347, encodeId=cb8f14e33471c, content=<a href='/topic/show?id=862be0746bc' target=_blank style='color:#2F92EE;'>#疾病风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70746, encryptionId=862be0746bc, topicName=疾病风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3c757221906, createdName=花花1368, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1499103, encodeId=ad8c149910355, content=<a href='/topic/show?id=bb6f89e145a' target=_blank style='color:#2F92EE;'>#血管疾病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89714, encryptionId=bb6f89e145a, topicName=血管疾病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ccb99370406, createdName=andy2090, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1627884, encodeId=f2b3162e884f9, content=<a href='/topic/show?id=ab4f66e8913' target=_blank style='color:#2F92EE;'>#激动剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66789, encryptionId=ab4f66e8913, topicName=激动剂)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=95bc21134754, createdName=medscijoin, createdTime=Mon Aug 15 07:31:25 CST 2022, time=2022-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1243650, encodeId=ba59124365058, content=JAMA上文章都是顶级的,谢谢梅斯及时上新, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=肿瘤克星, createdTime=Sat Aug 13 19:31:25 CST 2022, time=2022-08-13, status=1, ipAttribution=)]
    2022-08-13 肿瘤克星

    JAMA上文章都是顶级的,谢谢梅斯及时上新

    0

相关资讯

低钠盐,适用于全世界!哈医大学者Meta分析

结果显示,低钠盐使总死亡风险降低11%,心血管疾病死亡风险降低13%,心脏病发作或脑卒中风险降低11%。

中南大学研究发现,经常午睡可能增加高血压、中风风险

根据既往观察性研究,对于夜晚睡眠时间充足的中年人来说,每天午睡有效睡眠时间在15-30分钟左右最佳。

Nature Nanotechnol:突破!把血压计“纹”在身上,全天候监测并预警高血压危象

可导电的石墨烯电子纹身可持续收集皮肤传导的小电流,并通过机器学习算法分析血压结果,且测量血压准确性较高。

J Adv Nurs:影响中国居民减少食盐摄入的因素

研究探索了中国高血压患者食盐摄入对健康影响的认知以及在中国文化背景下维持健康行为的感知障碍。

Cardiovasc Diabetol:TyG指数变化轨迹与高血压患者卒中风险的相关性

定期监测 TyG 指数可能有助于及时识别高血压患者中卒中风险较高的个体